The genetics of Charcot–Marie–Tooth disease: Current trends and future implications for diagnosis and management

Application of Clinical Genetics

Volumn 8, Issue , 2015, Pages 235-243

  Chad Hoyle, J ^a   Isfort, Michael C ^a   Roggenbuck, Jennifer ^a   David Arnold, W ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Charcot Marie Tooth disease; Nerve conduction studies; Neurogenetic testing; Neuropathy; Next generation sequencing

Indexed keywords

ANTIGESTAGEN; ASCORBIC ACID; BACLOFEN; CURCUMIN; HISTONE DEACETYLASE INHIBITOR; MITOFUSIN 2; NALTREXONE; PERIPHERAL MYELIN PROTEIN 22; SORBITOL;

ANKLE FOOT ORTHOSIS; AUTOSOMAL RECESSIVE INHERITANCE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DISEASE ASSOCIATION; ECHOGRAPHY; ELECTRODIAGNOSIS; EXERCISE; GENE; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; GJB1 GENE; HEALTH CARE COST; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INHERITANCE; MFN2 GENE; MOLECULAR PATHOLOGY; NERVE CONDUCTION VELOCITY TEST; NEXT GENERATION SEQUENCING; NONHUMAN; ORTHOPEDIC SURGERY; PHENOTYPE; PMP22 GENE; REVIEW; SPLINT; THUMB OPPOSITION SPLINT; TREND STUDY;

EID: 84944875577     PISSN: None     EISSN: 1178704X     Source Type: Journal    
DOI: 10.2147/TACG.S69969     Document Type: Review

References (100)

1. Mroczek M, Kabzinska D, Kochanski A. Molecular pathogenesis, experimental therapy and genetic counseling in hereditary sensory neuropathies. Acta Neurobiol Exp (Wars). 2015;75(2):126-143.
2. Rotthier A, Baets J, Timmerman V, Janssens K. Mechanisms of disease in hereditary sensory and autonomic neuropathies. Nat Rev Neurol. 2012;8(2):73-85.
3. Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. J Neurol Neurosurg Psychiatr. 2012;83(1):6-14.
4. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980;103(2):259-280.
5. Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology. 2011;76(20): 1690-1696.
6. Sheth S, Francies K, Siskind CE, Feely SM, Lewis RA, Shy ME. Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. J Peripher Nerv Syst. 2008;13(4):299-304.
7. Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain. 2009;132(Pt 12):3252-3262.
8. Karol LA, Elerson E. Scoliosis in patients with Charcot-Marie-Tooth disease. J Bone Joint Surg Am. 2007;89(7):1504-1510.
9. Horacek O, Mazanec R, Morris CE, Kobesova A. Spinal deformities in hereditary motor and sensory neuropathy: a retrospective qualitative, quantitative, genotypical, and familial analysis of 175 patients. Spine. 2007;32(22):2502-2508.
10. Walker JL, Nelson KR, Stevens DB, Lubicky JP, Ogden JA, VandenBrink KD. Spinal deformity in Charcot-Marie-Tooth disease. Spine. 1994;19(9):1044-1047.
11. Novais EN, Bixby SD, Rennick J, Carry PM, Kim YJ, Millis MB. Hip dysplasia is more severe in Charcot-Marie-Tooth disease than in developmental dysplasia of the hip. Clin Orthop Relat Res. 2014;472(2): 665-673.
12. Carter GT, Jensen MP, Galer BS, et al. Neuropathic pain in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil. 1998;79(12):1560-1564.
13. Ramchandren S, Jaiswal M, Feldman E, Shy M. Effect of pain in pediatric inherited neuropathies. Neurology. 2014;82(9):793-797.
14. Ribiere C, Bernardin M, Sacconi S, et al. Pain assessment in Charcot-Marie-Tooth (CMT) disease. Ann Phys Rehabil Med. 2012;55(3): 160-173.
15. Zambelis T. Small fiber neuropathy in Charcot-Marie-Tooth disease. Acta Neurol Belg. 2009;109(4):294-297.
16. Jeong NY, Shin YH, Jung J. Neuropathic pain in hereditary peripheral neuropathy. J Exerc Rehabil. 2013;9(4):397-399.
17. Boentert M, Knop K, Schuhmacher C, Gess B, Okegwo A, Young P. Sleep disorders in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatr. 2014;85(3):319-325.
18. Luigetti M, Del Grande A, Testani E, et al. Restless leg syndrome in different types of demyelinating neuropathies: a single-center pilot study. J Clin Sleep Med. 2013;9(9):945-949.
19. Johnson NE, Sowden J, Dilek N, et al. Prospective study of muscle cramps in Charcot-Marie-Tooth disease. Muscle Nerve. 2015; 51(4):485-488.
20. Arnold WD, Flanigan KM. A practical approach to molecular diagnostic testing in neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012;23(3):589-608.
21. Blair IP, Nash J, Gordon MJ, Nicholson GA. Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet. 1996;58(3):472-476.
22. Murphy SM, Laura M, Blake J, Polke J, Bremner F, Reilly MM. Conduction block and tonic pupils in Charcot-Marie-Tooth disease caused by a myelin protein zero p.Ile112Thr mutation. Neuromuscul Disord. 2011;21(3):223-226.
23. Anand G, Maheshwari N, Roberts D, et al. X-linked hereditary motor sensory neuropathy (type 1) presenting with a stroke-like episode. Dev Med Child Neurol. 2010;52(7):677-679.
24. Sagnelli A, Piscosquito G, Chiapparini L, et al. X-linked Charcot-Marie-Tooth type 1: stroke-like presentation of a novel GJB1 mutation. J Peripher Nerv Syst. 2014;19(2):183-186.
25. McKinney JL, De Los Reyes EC, Lo WD, Flanigan KM. Recurrent central nervous system white matter changes in Charcot-Marie-tooth type X disease. Muscle Nerve. 2014;49(3):451-454.
26. Echaniz-Laguna A, Dubourg O, Carlier P, et al. Phenotypic spectrum and incidence of TRPV4 mutations in patients with inherited axonal neuropathy. Neurology. 2014;82(21):1919-1926.
27. Landoure G, Sullivan JM, Johnson JO, et al. Exome sequencing identifies a novel TRPV4 mutation in a CMT2C family. Neurology. 2012;79(2):192-194.
28. Santoro L, Manganelli F, Di Maio L, et al. Charcot-Marie-Tooth disease type 2C: a distinct genetic entity. Clinical and molecular characterization of the first European family. Neuromuscul Disord. 2002;12(4):399-404.
29. Bombelli F, Stojkovic T, Dubourg O, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol. 2014;71(8):1036-1042.
30. De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain. 1999;122(Pt 2):281-290.
31. Takashima H, Nakagawa M, Umehara F, et al. Gap junction protein beta 1 (GJB1) mutations and central nervous system symptoms in X-linked Charcot-Marie-Tooth disease. Acta Neurol Scand. 2003;107(1):31-37.
32. Huehne K, Benes V, Thiel C, et al. Novel mutations in the Charcot-Marie-Tooth disease genes PMP22, MPZ, and GJB1. Hum Mutat. 2003;21(1):100.
33. Mathis S, Corcia P, Tazir M, et al. Peripheral myelin protein 22 gene duplication with atypical presentations: a new example of the wide spectrum of Charcot-Marie-Tooth 1A disease. Neuromuscul Disord. 2014;24(6):524-528.
34. Meier C, Moll C. Hereditary neuropathy with liability to pressure palsies. Report of two families and review of the literature. J Neurol. 1982;228(2):73-95.
35. Pareyson D, Scaioli V, Taroni F, et al. Phenotypic heterogeneity in hereditary neuropathy with liability to pressure palsies associated with chromosome 17p11.2-12 deletion. Neurology. 1996;46(4):1133-1137.
36. Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22-33.
37. Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst. 2013;18(2):113-129.
38. Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type 1. Neurology. 1993;43(12):2664-2667.
39. Cottenie E, Menezes MP, Rossor AM, et al. Rapidly progressive asymmetrical weakness in Charcot-Marie-Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2013;23(5):399-403.
40. Michell AW, Laura M, Blake J, et al. GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment. J Neurol Neurosurg Psychiatr. 2009;80(6):699-700.
41. Gerding WM, Koetting J, Epplen JT, Neusch C. Hereditary motor and sensory neuropathy caused by a novel mutation in LITAF. Neuromuscul Disord. 2009;19(10):701-703.
42. Bouche P, Gherardi R, Cathala HP, Lhermitte F, Castaigne P. Peroneal muscular atrophy. Part 1. Clinical and electrophysiological study. J Neurol Sci. 1983;61(3):389-399.
43. Zaidman CM, Harms MB, Pestronk A. Ultrasound of inherited vs acquired demyelinating polyneuropathies. J Neurol. 2013;260(12):3115-3121.
44. Schreiber S, Oldag A, Kornblum C, et al. Sonography of the median nerve in CMT1A, CMT2A, CMTX, and HNPP. Muscle Nerve. 2013; 47(3):385-395.
45. Sugimoto T, Ochi K, Hosomi N, et al. Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy. J Neurol. 2013;260(10):2580-2587.
46. Andersson PB, Yuen E, Parko K, So YT. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology. 2000;54(1):40-44.
47. Roa BB, Garcia CA, Lupski JR. Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy. Int J Neurol. 1991;25-26: 97-107.
48. Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;86(8):873-878.
49. Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatr. 2012;83(7):706-710.
50. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9(10):562-571.
51. Ankala A, da Silva C, Gualandi F, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol. 2015;77(2):206-214.
52. Gess B, Schirmacher A, Boentert M, Young P. Charcot-Marie-Tooth disease: frequency of genetic subtypes in a German neuromuscular center population. Neuromuscul Disord. 2013;23(8):647-651.
53. Ostern R, Fagerheim T, Hjellnes H, Nygard B, Mellgren SI, Nilssen O. Diagnostic laboratory testing for Charcot Marie Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies. BMC Med Genet. 2013;14:94.
54. Choi BO, Koo SK, Park MH, et al. Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth disease. Hum Mutat. 2012;33(11):1610-1615.
55. Daud D, Griffin H, Douroudis K, et al. Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering. J Neurol. 2015;262(7):1673-1677.
56. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362(13):1181-1191.
57. Menezes MP, Waddell L, Lenk GM, et al. Whole exome sequencing identifies three recessive FIG4 mutations in an apparently dominant pedigree with Charcot-Marie-Tooth disease. Neuromuscul Disord. 2014;24(8):666-670.
58. Hoyer H, Braathen GJ, Busk OL, et al. Genetic diagnosis of Charcot-Marie-Tooth disease in a population by next-generation sequencing. Biomed Res Int. 2014;2014:210401.
59. Menotti F, Laudani L, Damiani A, Mignogna T, Macaluso A. An anterior ankle-foot orthosis improves walking economy in Charcot-Marie-Tooth type 1A patients. Prosthet Orthot Int. 2014;38(5):387-392.
60. Dufek JS, Neumann ES, Hawkins MC, O'Toole B. Functional and dynamic response characteristics of a custom composite ankle foot orthosis for Charcot-Marie-Tooth patients. Gait Posture. 2014;39(1): 308-313.
61. Ramdharry GM, Day BL, Reilly MM, Marsden JF. Foot drop splints improve proximal as well as distal leg control during gait in Charcot-Marie-Tooth disease. Muscle Nerve. 2012;46(4):512-519.
62. Phillips MF, Robertson Z, Killen B, White B. A pilot study of a crossover trial with randomized use of ankle-foot orthoses for people with Charcot-Marie-Tooth disease. Clin Rehabil. 2012;26(6):534-544.
63. Guillebastre B, Calmels P, Rougier PR. Assessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth disease. Am J Phys Med Rehabil. 2011;90(8):619-627.
64. Videler A, Eijffinger E, Nollet F, Beelen A. A thumb opposition splint to improve manual dexterity and upper-limb functioning in Charcot-Marie-Tooth disease. J Rehabil Med. 2012;44(3):249-253.
65. Wetmore RS, Drennan JC. Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease. J Bone Joint Surg Am. 1989;71(3):417-422.
66. Ortiz C, Wagner E. Tendon transfers in cavovarus foot. Foot Ankle Clin. 2014;19(1):49-58.
67. Boffeli TJ, Tabatt JA. Minimally invasive early operative treatment of progressive foot and ankle deformity associated with Charcot-Marie-Tooth disease. J Foot Ankle Surg. 2015;54(4):701-708.
68. Dreher T, Wolf SI, Heitzmann D, Fremd C, Klotz MC, Wenz W. Tibialis posterior tendon transfer corrects the foot drop component of cavovarus foot deformity in Charcot-Marie-Tooth disease. J Bone Joint Surg Am. 2014;96(6):456-462.
69. Piscosquito G, Reilly MM, Schenone A, et al. Is overwork weakness relevant in Charcot-Marie-Tooth disease? J Neurol Neurosurg Psychiatr. 2014;85(12):1354-1358.
70. Chetlin RD, Gutmann L, Tarnopolsky M, Ullrich IH, Yeater RA. Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription. Arch Phys Med Rehabil. 2004;85(8):1217-1223.
71. Burns J, Raymond J, Ouvrier R. Feasibility of foot and ankle strength training in childhood Charcot-Marie-Tooth disease. Neuromuscul Disord. 2009;19(12):818-821.
72. Vinci P, Esposito C, Perelli SL, Antenor JA, Thomas FP. Overwork weakness in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil. 2003;84(6):825-827.
73. Lindeman E, Leffers P, Spaans F, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial. Arch Phys Med Rehabil. 1995;76(7):612-620.
74. Maggi G, Monti Bragadin M, Padua L, et al. Outcome measures and rehabilitation treatment in patients affected by Charcot-Marie-Tooth neuropathy: a pilot study. Am J Phys Med Rehabil. 2011;90(8):628-637.
75. Fonkem E, Skordilis MA, Binkley EM, et al. Ethambutol toxicity exacerbating the phenotype of CMT2A2. Muscle Nerve. 2013;48(1): 140-144.
76. Beutler AS, Kulkarni AA, Kanwar R, et al. Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy. Ann Neurol. 2014;76(5):727-737.
77. Ursino G, Alberti MA, Grandis M, et al. Influence of comorbidities on the phenotype of patients affected by Charcot-Marie-Tooth neuropathy type 1A. Neuromuscul Disord. 2013;23(11):902-906.
78. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci. 2006;242(1-2):47-54.
79. Nakamura T, Hashiguchi A, Suzuki S, Uozumi K, Tokunaga S, Takashima H. Vincristine exacerbates asymptomatic Charcot-Marie-Tooth disease with a novel EGR2 mutation. Neurogenetics. 2012;13(1):77-82.
80. Hogan-Dann CM, Fellmeth WG, McGuire SA, Kiley VA. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA. 1984;252(20):2862-2863.
81. Cil T, Altintas A, Tamam Y, Battaloglu E, Isikdogan A. Low dose vincristine-induced severe polyneuropathy in a Hodgkin lymphoma patient: a case report (vincristine-induced severe polyneuropathy). J Pediatr Hematol Oncol. 2009;31(10):787-789.
82. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009;52(2):298-300.
83. Nishikawa T, Kawakami K, Kumamoto T, et al. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(7):519-521.
84. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother. 2000;34(10):1136-1138.
85. Lewis RA, McDermott MP, Herrmann DN, et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013;70(8): 981-987.
86. Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2009;8(12):1103-1110.
87. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011;10(4):320-328.
88. Gess B, Rohr D, Young P. Ascorbic acid and sodium-dependent vitamin C transporters in the peripheral nervous system: from basic science to clinical trials. Antioxid Redox Signal. 2013;19(17): 2105-2114.
89. Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004;10(4):396-401.
90. Burns J, Ouvrier RA, Yiu EM, Ryan MM. Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acid. J Peripher Nerv Syst. 2011;16(3):272-274.
91. Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol. 2007;61(1):61-72.
92. Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med. 2003;9(12): 1533-1537.
93. Patzko A, Bai Y, Saporta MA, et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain. 2012;135(Pt 12):3551-3566.
94. Bai Y, Patzko A, Shy ME. Unfolded protein response, treatment and CMT1B. Rare Dis. 2013;1:e24049.
95. d'Ydewalle C, Krishnan J, Chiheb DM, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med. 2011;17(8):968-974.
96. Attarian S, Vallat JM, Magy L, et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2014;9:199.
97. Chumakov I, Milet A, Cholet N, et al. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 2014;9:201.
98. Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 2005;65(5):681-689.
99. Sahenk Z, Galloway G, Clark KR, et al. AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy. Mol Ther. 2014;22(3):511-521.
100. d'Ydewalle C, Benoy V, Van Den Bosch L. Charcot-Marie-Tooth disease: emerging mechanisms and therapies. Int J Biochem Cell Biol. 2012;44(8):1299-1304.